PALISADE BIO INC
PALINASDAQ🏆 #3556 by market capEarnings Nov 9US Equity
$1.19▲ $0.00 (+0.00%)
Pre-market · at closeTrack PALI
Get earnings, price moves & breaking news on Telegram
24h▲ 0.0%
7d▼ 11.9%
14d▼ 22.7%
30d▼ 17.4%
ytd▼ 49.6%
1y▼ 43.9%
🏦Market Cap
$207M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
413.0x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.11 – $1.22
- 52-Week Range
- $1.21 – $2.86
- Volume (shares)
- 746,619
- Avg Volume (shares)
- —
- Shares Outstanding
- 174.3M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- $500,000
- P/E Ratio
- —
- P/S Ratio
- 413.0x
- EPS (TTM)
- $-0.64
- Dividend Yield
- —
- Dilution (1yr)
- +551.9%
PALISADE BIO INC
PALIFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$18M▲ +21.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▼ −11.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
55.7M▲ +551.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$133M▲ +$124M YoY
StockOtter · stockotter.spaceAbout PALISADE BIO INC
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
16 analysts
Strong Buy6
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.